China has become a key piece of Foresite Capital’s investment and company formation strategy. During the J.P. Morgan Healthcare Conference, Managing Director Michael Rome shared his thoughts on why ...

Healthcare providers and vendors are learning the hard way that hackers are relentless and resourceful, constantly adjusting ...

Although hospitals are interested in digital health, the sales cycle for tech companies is notoriously long. One factor behind the length of this cycle is the critical need for hospitals to ...

The U.S. Department of Health and Human Services unveiled 15 additional drugs chosen for the Medicare Drug Price Negotiation Program on Friday. Many healthcare leaders are applauding the list of ...

A targeted cancer therapy from AstraZeneca’s alliance with Daiichi Sankyo is now FDA approved to treat certain cases of advanced breast cancer, giving the British pharmaceutical giant another ...

Over the last two years, we’ve seen some of the most impactful scientific advancements in Alzheimer’s disease diagnostics and treatment compared to recent decades. With more accessible means ...

Normally, I do a decent job turning my work switch off during the holidays. However, this time, as the holidays approached, I couldn’t help but reflect on the state of our healthcare system ...

The pharmaceutical industry went through major changes in 2024, and there’s no sign of things slowing down in 2025. With innovation speeding up and patient needs constantly evolving, the ...

In this month’s episode, Senior Reporter Katie Adams discussed some of the executive moves, exits and layoffs that occurred recently in the healthcare sector. She also interviewed Claire ...

Merith Basey, executive director of Patients For Affordable Drugs, believes the Medicare price negotiation program is here to stay, no matter who is president and no matter how many Big Pharma ...

The FDA clinical hold keeps Neumora Therapeutics from catching up to the field of biopharmaceutical companies pursuing the same target for schizophrenia. But Neumora remains on track with its lead ...